Aditxt, Inc. (ADTX)
| Market Cap | 2.65M |
| Revenue (ttm) | 212,107 |
| Net Income (ttm) | -46.50M |
| Shares Out | 14.23M |
| EPS (ttm) | -845.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,602,983 |
| Open | 0.198 |
| Previous Close | 0.226 |
| Day's Range | 0.185 - 0.210 |
| 52-Week Range | 0.185 - 338.800 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 18, 2024 |
About ADTX
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ... [Read more]
Financial Performance
In 2023, Aditxt's revenue was $645,176, a decrease of -30.90% compared to the previous year's $933,715. Losses were -$32.70 million, 18.1% more than in 2022.
Financial StatementsNews
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced th...
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial...
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an ...
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today th...
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders...
Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an im...
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced th...
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced th...
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced th...
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a ...
Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing program...
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of ...
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc....
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update...
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced today that it ...
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its...
Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announ...
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women's health pio...
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiar...
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations...
Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations...
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations...
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai...
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. co...